Stock listing
NASDAQ:BIOA BioAge Labs, Inc. Stock
Home listing (NASDAQ) of BioAge Labs, Inc.
Follow BioAge Labs, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:BIOA
$4.28 USD -0.49 (-10.3%)
Close on Nov 20, 2026
- Day range
- $4.24 – $4.77 USDNov 20, 2026
- Volume
- 632,102 sharesNov 20, 2026
- Market cap
- $196.4M USDAt the close on Nov 20, 2026 · price × 45.90M shares outstanding
- 52-week range
- $4.24 – $25.96 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $5.05M USDMedian day 643,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BIOA · Home | $4.28 USD | -0.49 (-10.3%) | 632,102 | $4.60 | $4.77 | $4.235 | $4.77 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BIOA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.28 | -0.49 | -10.3% | $4.60 | $4.77 | $4.235 | 632,102 | |
| $4.77 | -0.33 | -6.5% | $5.13 | $5.13 | $4.77 | 640,564 | |
| $5.10 | -0.12 | -2.3% | $5.305 | $5.305 | $4.98 | 481,159 | |
| $5.22 | -0.33 | -5.9% | $5.50 | $5.64 | $5.08 | 689,013 | |
| $5.55 | -0.10 | -1.8% | $5.71 | $5.71 | $5.39 | 427,402 | |
| $5.65 | -0.22 | -3.7% | $5.735 | $5.869 | $5.47 | 471,444 | |
| $5.87 | +0.09 | +1.6% | $5.83 | $6.08 | $5.755 | 434,958 | |
| $5.78 | +0.09 | +1.6% | $5.62 | $5.90 | $5.54 | 490,739 | |
| $5.69 | +0.35 | +6.6% | $5.36 | $5.74 | $5.16 | 829,135 | |
| $5.34 | -0.20 | -3.6% | $5.31 | $5.51 | $5.24 | 683,436 | |
| $5.54 | -0.41 | -6.9% | $5.93 | $6.02 | $5.46 | 672,198 | |
| $5.95 | -0.01 | -0.2% | $6.03 | $6.30 | $5.74 | 613,069 | |
| $5.96 | +0.16 | +2.8% | $5.83 | $6.01 | $5.58 | 860,031 | |
| $5.80 | -0.07 | -1.2% | $6.00 | $6.02 | $5.54 | 688,852 | |
| $5.87 | -0.07 | -1.2% | $5.86 | $5.925 | $5.63 | 800,727 | |
| $5.94 | 0.00 | 0.0% | $5.95 | $6.255 | $5.82 | 845,300 | |
| $5.94 | +0.47 | +8.6% | $5.41 | $5.97 | $5.22 | 1,434,900 | |
| $5.47 | +0.48 | +9.6% | $4.98 | $5.51 | $4.92 | 1,108,000 | |
| $4.99 | -0.11 | -2.2% | $5.10 | $5.15 | $4.92 | 539,000 | |
| $5.10 | -0.43 | -7.8% | $5.48 | $5.48 | $5.05 | 464,200 | |
| $5.53 | +0.02 | +0.4% | $5.45 | $5.62 | $5.411 | 482,300 | |
| $5.51 | -0.05 | -0.9% | $5.61 | $5.70 | $5.43 | 568,500 | |
| $5.56 | +0.57 | +11.4% | $5.00 | $5.64 | $4.97 | 1,204,600 | |
| $4.99 | +0.15 | +3.1% | $4.84 | $5.11 | $4.82 | 1,245,200 | |
| $4.84 | -0.51 | -9.5% | $5.35 | $5.35 | $4.81 | 868,100 | |
| $5.35 | -0.07 | -1.3% | $5.48 | $5.50 | $5.28 | 811,300 | |
| $5.42 | -0.15 | -2.7% | $5.49 | $5.58 | $5.36 | 614,900 | |
| $5.57 | -0.37 | -6.2% | $5.90 | $5.90 | $5.54 | 638,500 | |
| $5.94 | -0.40 | -6.3% | $6.24 | $6.295 | $5.875 | 482,000 | |
| $6.34 | +0.13 | +2.1% | $6.21 | $6.47 | $6.145 | 667,300 | |
| $6.21 | -0.05 | -0.8% | $6.17 | $6.265 | $5.99 | 906,900 | |
| $6.26 | -0.03 | -0.5% | $6.23 | $6.675 | $6.17 | 799,500 | |
| $6.29 | -0.07 | -1.1% | $6.44 | $6.45 | $6.00 | 3,251,700 | |
| $6.36 | -0.25 | -3.8% | $6.65 | $6.65 | $6.25 | 781,200 | |
| $6.61 | -0.20 | -2.9% | $6.92 | $6.92 | $6.47 | 869,600 | |
| $6.81 | -0.28 | -3.9% | $7.06 | $7.17 | $6.70 | 591,100 | |
| $7.09 | -0.05 | -0.7% | $7.20 | $7.26 | $6.97 | 755,200 | |
| $7.14 | -0.04 | -0.6% | $7.19 | $7.27 | $7.07 | 424,900 | |
| $7.18 | +0.13 | +1.8% | $7.11 | $7.425 | $6.96 | 800,100 | |
| $7.05 | -0.16 | -2.2% | $7.26 | $7.295 | $7.03 | 630,300 | |
| $7.21 | -0.68 | -8.6% | $7.79 | $7.88 | $7.19 | 1,010,900 | |
| $7.89 | -0.57 | -6.7% | $8.43 | $8.49 | $7.68 | 618,500 | |
| $8.46 | +0.37 | +4.6% | $8.20 | $8.53 | $8.11 | 1,067,400 | |
| $8.09 | +0.03 | +0.4% | $8.07 | $8.10 | $7.73 | 787,000 | |
| $8.06 | -0.03 | -0.4% | $8.07 | $8.23 | $7.86 | 1,509,000 | |
| $8.09 | +0.34 | +4.4% | $7.85 | $8.36 | $7.70 | 940,100 | |
| $7.75 | -0.43 | -5.3% | $8.21 | $8.275 | $7.62 | 715,800 | |
| $8.18 | -0.30 | -3.5% | $8.48 | $8.50 | $8.02 | 643,500 | |
| $8.48 | -0.01 | -0.1% | $8.52 | $8.635 | $8.39 | 563,400 | |
| $8.49 | -0.16 | -1.8% | $8.71 | $8.89 | $8.28 | 672,100 | |
| $8.65 | -0.52 | -5.7% | $9.07 | $9.07 | $8.60 | 492,700 | |
| $9.17 | -0.225 | -2.4% | $9.38 | $9.40 | $9.02 | 488,300 | |
| $9.395 | -0.195 | -2.0% | $9.60 | $9.645 | $9.324 | 388,000 | |
| $9.59 | +0.09 | +0.9% | $9.39 | $9.76 | $9.39 | 314,500 | |
| $9.50 | -0.23 | -2.4% | $9.90 | $9.98 | $9.415 | 407,300 | |
| $9.73 | +0.21 | +2.2% | $9.59 | $10.05 | $9.425 | 541,300 | |
| $9.52 | +0.02 | +0.2% | $9.28 | $9.72 | $9.15 | 605,000 | |
| $9.50 | -0.15 | -1.6% | $9.61 | $9.63 | $9.20 | 1,032,100 | |
| $9.65 | -0.43 | -4.3% | $10.06 | $10.25 | $9.595 | 452,200 | |
| $10.08 | +0.24 | +2.4% | $9.93 | $10.23 | $9.80 | 475,300 | |
| $9.84 | -0.27 | -2.7% | $10.03 | $10.03 | $9.76 | 503,900 | |
| $10.11 | +0.73 | +7.8% | $9.55 | $10.13 | $9.55 | 498,300 | |
| $9.38 | -0.10 | -1.1% | $9.57 | $9.65 | $9.16 | 658,900 | |
| $9.48 | -0.21 | -2.2% | $9.78 | $9.916 | $9.48 | 453,400 | |
| $9.69 | -1.06 | -9.9% | $10.64 | $10.73 | $9.63 | 776,800 |
- Ticker
- NASDAQ:BIOA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 11, 2026
BioAge Labs to Present at Upcoming Investor Conferences
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 61 slides
Latest news
BioAge Labs to Present at Upcoming Investor Conferences
Nov 11, 2026
Closed $5.87 (+1.6%) on Nov 11, 2026
BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates
Nov 5, 2026
Closed $5.34 (-3.6%) on Nov 6, 2026
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema
Sep 8, 2026
Closed $9.40 (-2.0%) on Sep 8, 2026
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
Aug 5, 2026
Closed $11.27 (+2.6%) on Aug 6, 2026
HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction
Jul 14, 2026
Closed $22.78 (+4.6%) on Jul 14, 2026
BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk
Jun 16, 2026
Closed $20.49 (+3.3%) on Jun 16, 2026
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
May 8, 2026
Closed $17.99 (+1.0%) on May 8, 2026
R&D Day Presentation
May 7, 2026
Closed $17.99 (+1.0%) on May 8, 2026
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
May 4, 2026
Closed $16.68 (+0.4%) on May 5, 2026
BioAge Labs, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 42 in all · newest Nov 11, 2026 · oldest 2024
- Decks
- 2 decks · latest September 2026
Where BioAge Labs, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BIOA · Home listing · This page | NASDAQ | United States | USD |
| gettex:Y7G | gettex | Germany | EUR |
| Lang & Schwarz:A40D7P | Lang & Schwarz | Germany | EUR |
| BOATS:BIOA | BOATS | United States | USD |
| Tradegate:Y7G | Tradegate | Germany | EUR |
| LS Exchange:A40D7P | LS Exchange | Germany | EUR |
| Frankfurt:Y7G | Frankfurt | Germany | EUR |
| Dusseldorf:Y7G | Dusseldorf | Germany | EUR |
| Hamburg:Y7G | Hamburg | Germany | EUR |
| Munich:Y7G | Munich | Germany | EUR |
| Stuttgart:Y7G | Stuttgart | Germany | EUR |
Valuation
EV/sales −10.1× against a median of 9.8×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$87.20M USD
- P/E
- Loss
- EV/sales
- −10.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.6×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 2.06
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BioAge Labs, Inc. · NASDAQ:BIOA | US$196.4M | −US$87.20M | n/a | −10.1× | n/a | 0.6× | n/a | 0.0× | 2.06 |
| Hightide Therapeutics Inc · HKEX:2511 | US$204.6M | US$178.9M | n/a | n/a | n/a | 8.2× | n/a | 0.9× | n/a |
| PharmaEngine, Inc. · TPEX:4162 | US$204.2M | US$50.36M | 12.5× | 1.6× | 3.4× | 1.4× | 52.6% | 0.0× | n/a |
| Cabaletta Bio, Inc. · NASDAQ:CABA | US$201.9M | −US$97.45M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.89 |
| Bright Minds Biosciences Inc. · CSE:DRUG | US$199.5M | −US$15.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.32 |
| Newron Pharmaceuticals S.p.A. · SIX:NWRN | US$199.5M | US$206.2M | n/a | 9.8× | n/a | n/a | −69.2% | n/a | n/a |
| NervGen Pharma Corp. · NASDAQ:NGEN | US$198.4M | US$137.8M | n/a | n/a | n/a | 16.4× | n/a | 0.0× | 1.46 |
| Lineage Cell Therapeutics, Inc. · AMEX:LCTX | US$195.3M | US$152.1M | 111× | 14.0× | n/a | 2.9× | 16.2% | 0.0× | 1.33 |
| AC Immune SA · NASDAQ:ACIU | US$193.9M | US$110.5M | n/a | 4.7× | n/a | 6.0× | −181.9% | 0.1× | 1.56 |
| SillaJen, Inc. · KRX:215600 | US$193.5M | US$141.7M | n/a | 17.6× | n/a | 2.6× | −223.8% | 0.0× | n/a |
| AN2 Therapeutics, Inc. · NASDAQ:ANTX | US$192.8M | US$128.4M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.54 |
| Median of the others | US$198.9M | US$133.1M | 61.9× | 9.8× | 3.4× | 2.6× | −69.2% | 0.0× | 1.40 |
Forecasts
5 strong buy · 2 buy · 3 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 28.44 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.61 · 8 analysts
- Revenue, year to Dec 2026
- 6.81M · 11 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Kristen Fortney | Co-Founder, CEO |
| Dov Goldstein | Chief Financial Officer |
| Eric Morgen | Co-Founder, COO |
| Chris Patil | VP, Media |
| George Hartman | SVP, Chemistry |
| Joseph Rodgers | VP, Discovery Research |
| Julie Gammelgard | SVP, People |
| Kevin Wilhelmsen | VP, Biology |
| Naisha Shah | SVP, Data Science |
| Nancy Mitchell-Sweeney | VP & Head of Clinical Operations |
| Patrick Martin | SVP, Clinical Science |
| Paul Rubin | CMO & EVP, Research |
| Rusty Montgomery | SVP, Research |
| Sangita Ghosh | SVP, Technical Operations |
| Shane Barton | SVP, Finance |
| Yan Wang | SVP, Translational Aging Biology |
| Yvonne Van Gessel | VP, Nonclinical Development |
| Ann Neale | Chief Development Officer |
| BJ Sullivan | Chief Strategy Officer |
| Peng Leong | Chief Business Officer & Therapeutic Area Head, Brain Aging |
| Vijay Pande | Co-founder & Managing Partner, VZVC |
Board
| Director | Role |
|---|---|
| Jean-Pierre Garnier | Chair of the Board |
| Michael Davidson | Independent Director |
| Rekha Hemrajani | Independent Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · After close | −3.6% |
| Q2 2026 | Aug 5, 2026 · After close | +2.6% |
| Q1 2026 | May 8, 2026 · Before open | +0.9% |
| Q4 2025 | Mar 19, 2026 | −0.3% |
| Q3 2025 | Nov 6, 2025 · After close | −2.8% |
| Q2 2025 | Aug 6, 2025 · After close | −0.2% |
| Q1 2025 | May 6, 2025 · After close | +2.8% |
| Q4 2024 | Mar 20, 2025 | +1.1% |
| Q3 2024 | Nov 7, 2024 · After close | +7.6% |
| Q2 2024 | Aug 28, 2024 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 61 slides | September 2026 |
| Investor Day (May 2026) | Investor day | 106 slides | May 8, 2026 |
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock Made bigger: about US$115M · US$19.5 a share · Goldman Sachs & Co. LLC +2 Dealers: Goldman Sachs & Co. LLC (co-lead), Piper Sandler (co-lead), Citigroup (co-lead) Use of proceeds: R&D, clinical and manufacturing of product candidates incl. BGE-102, NLRP3 and APJ programs; working capital, capex, debt reduction, general corporate purposes | Jan 22, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$18.00 a share on Sep 25, 2024.
- Price
- US$18.00 a share
- Shares offered
- 11,000,000 shares of common stock
- Offering size
- US$198 million
- Underwriters' option
- Up to 1,650,000 more shares
- Underwriters
- Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, Citigroup · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 31, 2024 |
| Filed publicly | Sep 3, 2024 |
| Amended twice | Newest Sep 25, 2024 |
| Shares registered with an exchange | Sep 18, 2024 |
| Declared effective by the SEC | Sep 25, 2024 |
| Final prospectus, with the price | Sep 26, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 26, 2024 |
| EFFECT · Notice that a registration is effective | Sep 25, 2024 |
| S-1MEF · Registration of more shares for the same offering | Sep 25, 2024 |
| CERT · Exchange's certificate of listing | Sep 25, 2024 |
| CORRESP · Letter to the SEC | Sep 25, 2024 |
| S-1/A · Registration statement, amended | Sep 25, 2024 |
| UPLOAD · Letter from the SEC | Sep 23, 2024 |
| CORRESP · Letter to the SEC | Sep 23, 2024 |
| CORRESP · Letter to the SEC | Sep 23, 2024 |
| CORRESP · Letter to the SEC | Sep 18, 2024 |
All 24 filings
| Filing | Filed |
|---|---|
| 8-A12B · Registration of shares for listing on an exchange | Sep 18, 2024 |
| S-1/A · Registration statement, amended | Sep 18, 2024 |
| CORRESP · Letter to the SEC | Sep 12, 2024 |
| UPLOAD · Letter from the SEC | Sep 6, 2024 |
| CORRESP · Letter to the SEC | Sep 3, 2024 |
| S-1 · Registration statement | Sep 3, 2024 |
| UPLOAD · Letter from the SEC | Aug 9, 2024 |
| DRSLTR · Letter to the SEC with a draft | Aug 5, 2024 |
| DRS/A · Draft registration statement, amended | Aug 5, 2024 |
| UPLOAD · Letter from the SEC | Jul 18, 2024 |
| DRSLTR · Letter to the SEC with a draft | Jul 3, 2024 |
| DRS/A · Draft registration statement, amended | Jul 3, 2024 |
| UPLOAD · Letter from the SEC | Jun 28, 2024 |
| DRS · Draft registration statement | May 31, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 26, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.99M | 0 | 0 | 0 | 14.9M | 8.27M | 2.17M | 1.54M | 2.67M |
| Cost of revenue | 213.0K | 22.3M | 13.7M | 2.61M | 6.04M | 2.69M | |||
| Gross profit | 8.99M | -7.38M | -5.39M | -440.8K | -4.50M | -23.8K | |||
| Research and development | 74.0M | 59.0M | 33.9M | 30.5M | 5.47M | 7.20M | 20.3M | 15.2M | 16.6M |
| Selling, general and administrative | 27.8M | 19.2M | 14.5M | 9.45M | 10.4M | 6.54M | 6.59M | 6.17M | 5.03M |
| Operating income | -92.8M | -78.2M | -48.4M | -40.0M | -110.0M | -29.6M | -38.5M | -35.2M | -41.2M |
| Depreciation and amortization | 200.0K | 200.0K | 200.0K | 129.0K | 9.35M | 9.16M | 4.16M | 1.37M | 1.71M |
| EBITDA | -92.6M | -78.0M | -48.2M | -39.8M | -100.7M | -20.5M | -34.4M | -33.8M | -39.5M |
| Interest expense | 697.0K | 2.37M | 7.79M | 241.0K | 7.43M | ||||
| Income before tax | -80.6M | -71.1M | -63.9M | -39.7M | -102.1M | -28.3M | -41.2M | -47.2M | -33.7M |
| Income tax | 0 | 0 | 0 | 241.0K | 81.7K | 25.6K | -3.79K | 75.4K | 102.8K |
| Net income | -80.6M | -71.1M | -63.9M | -39.7M | -98.2M | -22.5M | -37.2M | -46.4M | -33.2M |
| Earnings per share, basic | -2.24 | -6.63 | -38.17 | -1.16 | -2.34 | -0.66 | -1.32 | -1.65 | -1.18 |
| Earnings per share, diluted | -2.24 | -6.63 | -38.17 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 188.9M | 354.3M | 21.6M | 27.6M | 4.63M | 16.2M | 6.97M | 51.0M | 83.7M |
| Short-term investments | 92.2M | 0 | |||||||
| Receivables | 769.0K | 0 | 4.86M | 986.9K | 978.6K | 476.9K | 755.0K | ||
| Inventory | 4.82M | 4.50M | 1.75M | 1.80M | 2.42M | ||||
| Current assets | 286.8M | 357.1M | 25.3M | 28.0M | 15.2M | 31.4M | 10.8M | 57.1M | 95.0M |
| Property, plant and equipment | 963.0K | 591.0K | 323.0K | ||||||
| Goodwill | 625.4K | 625.4K | 625.4K | 692.8K | |||||
| Total assets | 294.9M | 358.2M | 25.9M | 28.4M | 69.5M | 161.3M | 143.1M | 152.4M | 114.1M |
| Accounts payable | 2.67M | 2.00M | 1.87M | 2.26M | 6.15M | 6.02M | 15.8M | 983.5K | 29.5K |
| Current liabilities | 20.1M | 27.8M | 58.2M | 5.86M | 11.3M | 45.3M | 29.7M | 22.9M | 17.8M |
| Long-term debt | 0 | 2.50M | 8.20M | 2.25M | |||||
| Total debt | 2.65M | 8.50M | 14.2M | 2.47M | 37.6M | 52.3M | 40.1M | 37.6M | 29.7M |
| Total liabilities | 22.8M | 35.1M | 66.6M | 141.0M | 47.7M | 112.8M | 96.7M | 94.9M | 49.1M |
| Shareholders' equity | 272.1M | 323.1M | -173.4M | -112.6M | 21.9M | 48.5M | 46.4M | 57.5M | 65.0M |
| Shares outstanding | 37.4M | 35.9M | 1.67M | 34.2M | 41.9M | 34.2M | 28.2M | 28.2M | 28.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -81.6M | -51.5M | -37.4M | -36.2M | -29.8M | -37.6M | -32.2M | -22.5M | -27.5M |
| Capital spending | -719.0K | -366.0K | -166.0K | -103.0K | 0 | 0 | 0 | 0 | -12.8M |
| Free cash flow | -82.3M | -51.9M | -37.5M | -36.3M | -29.8M | -37.6M | -32.2M | -22.5M | -40.3M |
| Cash from investing | -95.2M | -366.0K | -266.0K | -103.0K | |||||
| Cash from financing | 11.5M | 381.2M | 34.9M | 2.50M | 18.8M | 47.2M | 54.9M | 78.7M | 99.9M |
| Share buybacks | -4.63M | -16.2M | -6.97M | -51.0M | -83.7M | ||||
| Change in cash | -165.5M | 329.4M | -2.69M | -33.5M | -11.5M | 9.19M | -44.1M | -32.7M | 58.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 8-K · Current report | Oct 2, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
All 158 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 8, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 24, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 21, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 21, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 21, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2026 | Other filings | SEC |
| S-3ASR · Registration statement | Mar 24, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 24, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 24, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 2, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 22, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 22, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Jan 20, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 13, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 4, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 4, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| S-3/A · Registration statement, amended | Nov 5, 2025 | Offer document | SEC |
| S-3/A · Registration statement, amended | Nov 5, 2025 | Offer document | SEC |
| S-3 · Registration statement | Oct 2, 2025 | Offer document | SEC |
| S-3 · Registration statement | Oct 2, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 11, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 4, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 17, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 17, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 17, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Mar 20, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| 4/A · Change in ownership, amended | Mar 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Oct 7, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Oct 4, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| SC 13D · Big-stake notice | Sep 30, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| SEC STAFF LETTER | Sep 27, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 27, 2024 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Sep 26, 2024 | Offer document | SEC |
| 424B4 · Prospectus | Sep 26, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 26, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Sep 25, 2024 | Insider trade | SEC |
| S-1MEF · Registration of more shares for the same offering | Sep 25, 2024 | Offer document | SEC |
| 3 · Initial statement of ownership | Sep 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 25, 2024 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Sep 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 25, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 25, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 18, 2024 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Sep 18, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Sep 18, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 12, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 6, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 3, 2024 | Other filings | SEC |
| S-1 · Registration statement | Sep 3, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 9, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Aug 5, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Aug 5, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jul 18, 2024 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Jul 3, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Jul 3, 2024 | Offer document | SEC |
| SEC STAFF LETTER | Jul 2, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 28, 2024 | Other filings | SEC |
| DRS · Draft registration statement | May 31, 2024 | Offer document | SEC |
| D | Feb 13, 2024 | Other filings | SEC |
Cap table
Built by 6ix from BioAge Labs, Inc.’s releases · as of Jul 31, 2026
- Common shares
- 45,896,909
- Fully diluted
- 45,896,909
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 45,896,909 | Jul 31, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Jul 31, 2026 | 45,896,909 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| James Healy Other companies: Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); Rapport Therapeutics, Inc. (Director · Since at least Jun 6, 2024); ArriVent BioPharma, Inc. (Director · Since at least Jan 25, 2024); Y mAbs Therapeutics (Director · Since at least Jun 12, 2019); CinCor Pharma Inc (Director · Jan 6, 2022 – Nov 28, 2022 · Past); Bolt Biotherapeutics, Inc. (Director · Feb 4, 2021 – Jun 12, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Mar 18, 2024 · Past); Coherus Oncology, Inc. (Director · May 22, 2019 – Jan 7, 2022 · Past); Natera, Inc. (Director · Sep 14, 2018 – Apr 25, 2025 · Past) | Director · Since at least Sep 25, 2024 |
| Rekha Hemrajani Other companies: LB Pharmaceuticals Inc (Director · Since at least Sep 10, 2025); MaxCyte, Inc. (Non-Executive Director · Since at least Jun 29, 2022); ALX Oncology Holdings Inc. (Director · Since at least Jun 15, 2022) | Director · Since at least Apr 17, 2024 |
| Shane Barton Other companies: Precision BioSciences, Inc. (VP & Corporate Controller · Jan 1, 2021 – Jun 7, 2023 · Past) | SVP, Finance · Since at least Sep 25, 2024 |
| Vijay Pande Other companies: Nautilus Biotechnology, Inc. (Director · Jun 14, 2024 – Jun 14, 2024 · Past) | Director · Since at least Sep 25, 2024 |
| Ann Neale | Chief Development Officer · Since at least Nov 5, 2026 |
| BJ Sullivan | Chief Strategy Officer · Since at least Apr 13, 2026 |
| Chris Patil | VP, Media · Since at least Sep 8, 2026 |
| Dov Goldstein | Chief Financial Officer · Since at least Apr 24, 2026 |
| Eric Morgen | Co-Founder, COO · Since at least Jun 17, 2025 |
| George Hartman | SVP, Chemistry · Since at least Nov 5, 2026 |
All 25 people
| Person | Seat |
|---|---|
| Jean-Pierre Garnier | Chair of the Board · Since at least Nov 7, 2024 |
| Joseph Rodgers | VP, Discovery Research · Since at least Nov 5, 2026 |
| Julie Gammelgard | SVP, People · Since at least Nov 5, 2026 |
| Kevin Wilhelmsen | VP, Biology · Since at least Nov 5, 2026 |
| Kristen Fortney | Co-Founder, CEO · Since at least Sep 8, 2026 |
| Michael Davidson | Independent Director · Since at least May 7, 2026 |
| Naisha Shah | SVP, Data Science · Since at least Nov 5, 2026 |
| Nancy Mitchell-Sweeney | VP & Head of Clinical Operations · Since at least Nov 5, 2026 |
| Patrick Martin | SVP, Clinical Science · Since at least Nov 5, 2026 |
| Paul Rubin | CMO & EVP, Research · Since at least Apr 3, 2026 |
| Peng Leong | Chief Business Officer & Therapeutic Area Head, Brain Aging · Since at least Jun 16, 2026 |
| Rusty Montgomery | SVP, Research · Since at least Nov 5, 2026 |
| Sangita Ghosh | SVP, Technical Operations · Since at least Nov 5, 2026 |
| Yan Wang | SVP, Translational Aging Biology · Since at least Nov 5, 2026 |
| Yvonne Van Gessel | VP, Nonclinical Development · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about BioAge Labs, Inc.